{
  "id": 15825851,
  "title": "Would subsidizing weight-loss drugs make health care fairer?",
  "url": "https://urgent.news/2026/10/21/would-subsidizing-weight-loss-drugs-make-health-care-fairer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-21T00:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-subsidizing-weight-loss-drugs-health.html"
  },
  "original_language": "en",
  "account": "The use of GLP-1 medicines, such as Ozempic, Wegovy, and Mounjaro, has revolutionized obesity treatment in Australia, with nearly half a million people currently utilizing these medications. However, the majority of users pay out-of-pocket, with costs ranging from $200 to $700 per month. This financial burden disproportionately affects those living with obesity who do not have diabetes, which costs the Australian economy billions annually. A review involving nearly 28,000 individuals found that semaglutide, the active ingredient in these medicines, led to an average weight loss of 11% over two years, with most people maintaining their weight loss while continuing treatment. Yet, many stop taking the medication due to affordability, often regaining around 60% of their lost weight within a year. This raises the question of whether subsidizing these medicines would make healthcare in Australia more equitable. While subsidies could improve treatment access for those who cannot afford them, they would not address the underlying social and environmental factors contributing to obesity, such as access to nutritious food, affordable healthcare, and opportunities for physical activity. Addressing these factors and reducing the need for treatment is crucial in making healthcare more equitable.",
  "summary": "GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity, but access to them in Australia increasingly depends on something much less medical: whether you can afford them.",
  "key_points": [
    "Nearly 500,000 Australians use GLP-1 medicines like Ozempic and Wegovy.",
    "Monthly costs range from $200 to $700, creating a financial burden.",
    "Subsidizing medicines could improve treatment access but not address obesity's root causes."
  ],
  "editors_take": "Subsidizing these medications could bridge the gap in treatment access for those without diabetes, though it fails to tackle the broader social and environmental drivers of the obesity epidemic.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}